Stringhini, SilviaWisniak, AniaPiumatti, GiovanniAzman, Andrew SLauer, Stephen ABaysson, HélèneDe Ridder, DavidPetrovic, DusanSchrempft, StephanieMarcus, KailingYerly, SabineArm Vernez, IsabelleKeiser, OliviaHurst, SamiaPosfay-Barbe, Klara MTrono, DidierPittet, DidierGétaz, LaurentChappuis, FrançoisEckerle, IsabellaVuilleumier, NicolasMeyer, BenjaminFlahault, AntoineKaiser, LaurentGuessous, Idris2020-06-192020-06-192020-06-192020-06-1110.1016/S0140-6736(20)31304-0https://infoscience.epfl.ch/handle/20.500.14299/169465Assessing the burden of COVID-19 on the basis of medically attended case numbers is suboptimal given its reliance on testing strategy, changing case definitions, and disease presentation. Population-based serosurveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies provide one method for estimating infection rates and monitoring the progression of the epidemic. Here, we estimate weekly seroprevalence of anti-SARS-CoV-2 antibodies in the population of Geneva, Switzerland, during the epidemic.text::journal::journal article::research article